Vertex Pharmaceuticals Incorporated
Stock Forecast, Prediction & Price Target
Vertex Pharmaceuticals Incorporated Financial Estimates
Vertex Pharmaceuticals Incorporated Revenue Estimates
Vertex Pharmaceuticals Incorporated EBITDA Estimates
Vertex Pharmaceuticals Incorporated Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $7.57B N/A | $8.93B 17.90% | $9.86B 10.50% | Avg: $11.64B Low: $11.64B High: $11.64B avg. 17.97% | Avg: $12.79B Low: $12.79B High: $12.79B avg. 9.93% | Avg: $14.01B Low: $14.01B High: $14.01B avg. 9.50% | Avg: $15.16B Low: $15.16B High: $15.16B avg. 8.18% |
Net Income
% change YoY
| $2.34B N/A | $3.32B 41.83% | $3.61B 8.95% | Avg: $4.72B Low: $4.72B High: $4.72B avg. 30.64% | Avg: $5.40B Low: $5.40B High: $5.40B avg. 14.29% | Avg: $5.87B Low: $5.87B High: $5.87B avg. 8.76% | Avg: $6.47B Low: $6.47B High: $6.47B avg. 10.19% |
EBITDA
% change YoY
| $2.78B N/A | $4.34B 55.80% | $4.60B 5.98% | Avg: $4.93B Low: $4.93B High: $4.93B avg. 7.11% | Avg: $5.42B Low: $5.42B High: $5.42B avg. 9.93% | Avg: $5.93B Low: $5.93B High: $5.93B avg. 9.50% | Avg: $6.42B Low: $6.42B High: $6.42B avg. 8.18% |
EPS
% change YoY
| $9.09 N/A | $12.97 42.68% | $14.05 8.32% | Avg: $18.15 Low: $18.15 High: $18.15 avg. 29.20% | Avg: $20.75 Low: $20.75 High: $20.75 avg. 14.29% | Avg: $22.57 Low: $22.57 High: $22.57 avg. 8.76% | Avg: $24.87 Low: $24.87 High: $24.87 avg. 10.19% |
Operating Expenses
% change YoY
| $3.89B N/A | $3.48B -10.43% | $4.77B 37.01% | Avg: $1.43B Low: $1.43B High: $1.43B avg. -70.03% | Avg: $1.57B Low: $1.57B High: $1.57B avg. 9.93% | Avg: $1.72B Low: $1.72B High: $1.72B avg. 9.50% | Avg: $1.86B Low: $1.86B High: $1.86B avg. 8.18% |
FAQ
What is Vertex Pharmaceuticals Incorporated stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 15.97% in 2025-2028.
We have gathered data from N/A analysts. Their low estimate is 4.72B, average is 4.72B and high is 4.72B.
What is Vertex Pharmaceuticals Incorporated stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 11.39% in 2025-2028.
We have gathered data from N/A analysts. Their low revenue estimate is $11.64B, average is $11.64B and high is $11.64B.
What is Vertex Pharmaceuticals Incorporated stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 15.61% in 2025-2028.
We have gathered data from N/A analysts. Their low earnings per share estimate is $18.15, average is $18.15 and high is $18.15.